Quinn William P.
SEC Form 4 history for the last 180 days across 1 company, 4 transactions and 1 filing.
Period: Last 180 days
Trade dates in this period: Jun 5, 2026 – Sep 18, 2026
Transaction history, summary figures and purchase returns cover the last 180 days. Earlier activity is excluded from those sections.
Latest insider transactions
Form 4 filings from the last 180 days.| Company | Activity | Disclosed value | Filed (ET) |
|---|---|---|---|
BOLTBolt Biotherapeutics, Inc. | President · CCPRES, CC SellForm 4 code S. Open-market or private sale of a non-derivative or derivative security. | −$29.6kView disclosure → | |
BOLTBolt Biotherapeutics, Inc. | President · CCPRES, CC SellForm 4 code S. Open-market or private sale of a non-derivative or derivative security. | −$21.7kView disclosure → | |
BOLTBolt Biotherapeutics, Inc. | President · CCPRES, CC SellForm 4 code S. Open-market or private sale of a non-derivative or derivative security. | −$7.13kView disclosure → | |
BOLTBolt Biotherapeutics, Inc. | President · CCPRES, CC BuyForm 4 code P. Open-market or private purchase of a non-derivative or derivative security. | $2.47kView disclosure → |
Latest Form 4 facts
Quick context from source filings
The insider reported a sale at Bolt Biotherapeutics, Inc. on Sep 18, 2026 valued at $29,554.80.
Review SEC filingThe insider reported a buy at Bolt Biotherapeutics, Inc. on Jun 5, 2026 valued at $2,469.01.
Review SEC filingMonthly open-market activity
Last 2 reported months · purchases and sales
View exact monthly values
| Month | Purchases | Sales | Buy value | Sale value | Net value |
|---|---|---|---|---|---|
| Jun 2026 | 1 | 0 | $2,469.01 | $0 | +$2,469.01 |
| Sep 2026 | 0 | 3 | $0 | $58,402.16 | −$58,402.16 |
Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.
Ownership and transaction size
Ownership and ticket size
Filing-only signals
Deterministic matches in this insider's history
Associated companies
Counts cover all available history, including outside the summary period
Open-market buy performance
90-day forward return on this insider's open-market purchases
No purchases currently have the price observations needed for a 90-day return. This may reflect incomplete price coverage or purchases that have not reached the return window.
How reported shareholdings evolved
Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.
4 observations · Jun 5, 2026 – Sep 18, 2026. Window ends at the latest available report, not today.
View exact observations and source transactions
| Transaction date | Shares held after | Filed | Source |
|---|---|---|---|
| Jun 5, 2026 | 2,950 | Sep 21, 2026 | View transaction |
| Sep 16, 2026 | 41,061 | Sep 21, 2026 | View transaction |
| Sep 17, 2026 | 34,516 | Sep 21, 2026 | View transaction |
| Sep 18, 2026 | 25,384 | Sep 21, 2026 | View transaction |
Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.
Quinn William P. Insider Activity FAQ
SEC Form 4 context
Who is Quinn William P.?
Quinn William P. is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001724190.
Which companies has Quinn William P. reported transactions for?
Bolt Biotherapeutics, Inc.
When was Quinn William P.'s latest insider buy?
The insider reported a buy at Bolt Biotherapeutics, Inc. on Jun 5, 2026 valued at $2,469.01.
When was Quinn William P.'s latest insider sale?
The insider reported a sale at Bolt Biotherapeutics, Inc. on Sep 18, 2026 valued at $29,554.80.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.